Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US - Reuters

Novo Nordisk is launching a discounted subscription program for Wegovy, its popular weight-loss drug, targeting uninsured and underinsured Americans who pay out of pocket. The move addresses a growing barrier to access for self-pay patients, who have faced steep prices as demand for GLP-1 weight-loss medications has surged. Wegovy has become one of the most sought-after drugs in the U.S., but high costs have limited its reach beyond those with insurance coverage or sufficient means. By offering reduced pricing through a subscription model, Novo Nordisk aims to expand its market while also undercutting competition in the fast-growing weight-loss drug category. The initiative reflects broader industry pressure to make these high-demand medications more affordable as regulatory scrutiny and consumer demand for pricing transparency intensify.